JP2019532619A5 - - Google Patents

Download PDF

Info

Publication number
JP2019532619A5
JP2019532619A5 JP2019505381A JP2019505381A JP2019532619A5 JP 2019532619 A5 JP2019532619 A5 JP 2019532619A5 JP 2019505381 A JP2019505381 A JP 2019505381A JP 2019505381 A JP2019505381 A JP 2019505381A JP 2019532619 A5 JP2019532619 A5 JP 2019532619A5
Authority
JP
Japan
Prior art keywords
antibody
seq
antigen
binding fragment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019505381A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532619A (ja
JP7214623B2 (ja
Filing date
Publication date
Priority claimed from NL2017270A external-priority patent/NL2017270B1/en
Application filed filed Critical
Publication of JP2019532619A publication Critical patent/JP2019532619A/ja
Publication of JP2019532619A5 publication Critical patent/JP2019532619A5/ja
Priority to JP2021166154A priority Critical patent/JP7440473B2/ja
Application granted granted Critical
Publication of JP7214623B2 publication Critical patent/JP7214623B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019505381A 2016-08-02 2017-08-01 ヒトctla-4に対する抗体 Active JP7214623B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021166154A JP7440473B2 (ja) 2016-08-02 2021-10-08 ヒトctla-4に対する抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2017270 2016-08-02
NL2017270A NL2017270B1 (en) 2016-08-02 2016-08-02 New anti-hCTLA-4 antibodies
PCT/IB2017/054697 WO2018025178A1 (en) 2016-08-02 2017-08-01 Antibodies against human ctla-4

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021166154A Division JP7440473B2 (ja) 2016-08-02 2021-10-08 ヒトctla-4に対する抗体

Publications (3)

Publication Number Publication Date
JP2019532619A JP2019532619A (ja) 2019-11-14
JP2019532619A5 true JP2019532619A5 (OSRAM) 2020-09-10
JP7214623B2 JP7214623B2 (ja) 2023-01-30

Family

ID=57104133

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019505381A Active JP7214623B2 (ja) 2016-08-02 2017-08-01 ヒトctla-4に対する抗体
JP2021166154A Active JP7440473B2 (ja) 2016-08-02 2021-10-08 ヒトctla-4に対する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021166154A Active JP7440473B2 (ja) 2016-08-02 2021-10-08 ヒトctla-4に対する抗体

Country Status (9)

Country Link
US (1) US10808030B2 (OSRAM)
EP (1) EP3494137B1 (OSRAM)
JP (2) JP7214623B2 (OSRAM)
CN (1) CN110088134B (OSRAM)
AR (1) AR109276A1 (OSRAM)
ES (1) ES3038117T3 (OSRAM)
NL (1) NL2017270B1 (OSRAM)
TW (1) TW201808997A (OSRAM)
WO (1) WO2018025178A1 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3026172A1 (en) 2016-06-02 2017-12-07 Ultimovacs As A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
US12139536B2 (en) * 2017-06-08 2024-11-12 Antibody Biopharm Inc. Guided combinational therapeutic antibody
CN110272490B (zh) * 2018-03-14 2021-05-14 上海开拓者生物医药有限公司 靶向ctla-4抗体、其制备方法和用途
CN112399973B (zh) * 2018-06-05 2022-12-16 江苏康宁杰瑞生物制药有限公司 二聚体及其用途
CN110760002A (zh) * 2018-07-25 2020-02-07 南京金斯瑞生物科技有限公司 人源化抗人ctla4单克隆抗体及其制备方法和用途
EP3617230A1 (en) * 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
US20230132385A9 (en) * 2018-09-20 2023-04-27 Tikcro Technologies Ltd. Antibodies specific to ctla-4 and uses thereof
CA3123338A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
CN119930820A (zh) * 2018-12-27 2025-05-06 吉加根公司 抗ctla-4结合蛋白及其使用方法
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
GB201905552D0 (en) * 2019-04-18 2019-06-05 Kymab Ltd Antagonists
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ose免疫治療公司 包含il-7變體之雙官能分子
CN115626956A (zh) * 2020-01-16 2023-01-20 三优生物医药(上海)有限公司 Ctla-4结合分子及其用途
US20230092707A1 (en) * 2020-03-05 2023-03-23 Merck Sharp & Dohme Llc Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-ctla4 antibody, and an anti-tigit antibody
WO2021178814A1 (en) * 2020-03-06 2021-09-10 Regeneron Pharmaceuticals, Inc. Anti-gitr antibodies and uses thereof
CN115551892A (zh) * 2020-03-26 2022-12-30 艾提欧生物疗法有限公司 用于耗竭调节性t细胞的双特异性融合蛋白
JP7440724B2 (ja) * 2020-04-13 2024-02-29 ビオシオン インコーポレイテッド Ctla4に結合する抗体及びその使用
TW202216768A (zh) 2020-06-22 2022-05-01 美商恩格姆生物製藥公司 Lair-1結合劑及其使用方法
IL298825A (en) * 2020-07-02 2023-02-01 Gigagen Inc ANTI-CTLA-4 binding proteins and methods of using them
CN115812081A (zh) * 2020-07-21 2023-03-17 上海君实生物医药科技股份有限公司 抗ctla-4抗体及其用途
CN114437228B (zh) * 2020-10-30 2024-02-06 中国科学院生物物理研究所 一种il-2与抗体亚单位构成的双功能融合蛋白
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
WO2022214652A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
US20240182571A1 (en) 2021-04-09 2024-06-06 Ose Immunotherapeutics New scaffold for bifunctional molecules with improved properties
WO2023240287A1 (en) * 2022-06-10 2023-12-14 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
JP2025525886A (ja) 2022-08-02 2025-08-07 オーエスイー・イミュノセラピューティクス Cd28に対する多機能性分子
WO2024200826A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof
WO2024200823A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2025061993A1 (en) 2023-09-21 2025-03-27 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2025061994A1 (en) 2023-09-21 2025-03-27 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5351481A (en) 1992-06-26 1994-10-04 Flowmaster, Inc. Muffler assembly with balanced chamber and method
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69427974T2 (de) 1993-04-29 2001-12-06 Unilever N.V., Rotterdam Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
JPH10508205A (ja) 1995-04-25 1998-08-18 バクスター インターナショナル インコーポレイテッド 肝細胞および膵臓ランゲルハンス島細胞を単離するためのコラーゲナーゼおよびキモパパインを含有する組成物
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク. 免疫したゼノマウス(XenoMouse)に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6033674A (en) 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
ATE477273T1 (de) 1998-12-01 2010-08-15 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
WO2000037504A2 (en) * 1998-12-23 2000-06-29 Pfizer Inc. Human monoclonal antibodies to ctla-4
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) * 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
JP2003520828A (ja) * 2000-01-27 2003-07-08 ジェネティクス インスティテュート,エルエルシー Ctla4(cd152)に対する抗体、これを含む結合体、およびその使用
KR100787073B1 (ko) 2000-06-28 2007-12-21 글리코파이, 인크. 변형된 당단백질의 제조방법
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US20020150588A1 (en) 2000-09-21 2002-10-17 Allison James P. SPAS-1 cancer antigen
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
EA013563B1 (ru) 2000-10-06 2010-06-30 Киова Хакко Кирин Ко., Лтд. Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2455365C (en) 2001-08-03 2014-07-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
AU2003226356A1 (en) 2002-04-12 2003-10-27 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
JP2007509067A (ja) 2003-10-15 2007-04-12 メディミューン,インコーポレーテッド リステリアに基づくEphA2ワクチン
US7592326B2 (en) 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
CA2560058C (en) 2004-03-15 2011-10-18 David K.R. Karaolis A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
DE602005022871D1 (de) 2004-06-07 2010-09-23 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
CA2573745A1 (en) 2004-07-21 2007-01-12 Glycofi, Inc. Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform
DE102004063494A1 (de) * 2004-12-23 2006-07-13 Tegenero Ag Antikörper
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
US7968300B2 (en) * 2007-11-21 2011-06-28 Li-Te Chin Method of isolating regulatory T cells from human samples
US8263073B2 (en) * 2008-02-04 2012-09-11 Medarex, Inc. Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof
US8840881B2 (en) 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
US8450293B2 (en) 2010-08-10 2013-05-28 Rutgers, The State University Of New Jersey Synthesis and characterization of C8 analogs of c-di-GMP
ES2684684T3 (es) 2010-11-17 2018-10-04 Aduro Biotech, Inc. Métodos y composiciones para inducir una respuesta inmune al EGFRVIII
AU2013358892B2 (en) 2012-12-13 2018-06-21 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
JP2016524593A (ja) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
ES2822584T3 (es) 2013-05-03 2021-05-04 Univ California Inducción de dinucleótidos cíclicos del interferón tipo I
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CN107148424B (zh) 2014-12-16 2021-01-08 凯拉治疗股份公司 用于诱导细胞因子的环状二核苷酸
WO2017011444A1 (en) 2015-07-13 2017-01-19 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating b cell cancers
EA034786B1 (ru) 2015-08-13 2020-03-20 Мерк Шарп И Доум Корп. Циклические динуклеотидные соединения в качестве агонистов sting
WO2018035710A1 (en) * 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
FI3551660T3 (fi) * 2016-12-07 2023-12-11 Agenus Inc Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä

Similar Documents

Publication Publication Date Title
JP2019532619A5 (OSRAM)
JP7682789B2 (ja) B7-H3のIgVドメインに対するモノクローナル抗体及びその使用
CN112955471B (zh) Cd3抗体及其药物用途
JP2017149720A5 (OSRAM)
JP2018523493A5 (OSRAM)
JP2020508655A5 (OSRAM)
JP2019535250A5 (OSRAM)
JP2019524693A5 (OSRAM)
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
RU2017123549A (ru) Антитела, нацеленные на антиген созревания в-клеток, и способы их применения
JP2018508214A5 (OSRAM)
JP2019520797A5 (OSRAM)
RU2022102446A (ru) Биспецифические связывающие белки и пути их применения
JP2012519492A5 (OSRAM)
JP2017531427A5 (OSRAM)
JP2018512175A5 (OSRAM)
JP2013506428A5 (OSRAM)
JP2018522888A5 (OSRAM)
JP2020514277A5 (OSRAM)
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
JP2015506912A5 (OSRAM)
JP2017506067A5 (OSRAM)
JP2012012402A5 (OSRAM)
CN108138172B (zh) 抗体
JP2018507188A5 (OSRAM)